Add to ORKGProphylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allerg
Birch pollen-allergic subjects produce polyclonal cross-reactive IgE antibodies that mediate pollen-...
We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both f...
Specific allergen immunotherapy (SIT) is disease-modifying and efficacious. However, the use of who...
IgE-mediated allergy to birch pollen affects more than 100 million patients world-wide. Bet v 1, a 1...
Background Allergy vaccines should be easily applicable, safe, and efficacious. For Bet v 1mediated...
A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes u...
Careful selection of dominant T cell epitope peptides of major allergens that display degeneracy for...
Background. Specific immunotherapy using recombinant allergens is clinically effective; still wild-t...
Background. Specific immunotherapy using recombinant allergens is clinically effective; still wild-t...
BackgroundBet v 1 is the main sensitizing allergen in birch pollen. Like many other major allergens,...
BACKGROUND: Synthetic contiguous overlapping peptides (COPs) may represent an alternative to allerge...
Allergen-reactive CD4+ T cells are implicated in the pathogenesis of allergic disease. Peptide immun...
<p>IgE binding properties of Bet v 1.0401 batches were tested by ELISA. Results are presented as mea...
Background Recombinant hypoallergenic allergen derivatives have been used in clinical immunotherapy ...
ABSTRACTCross-reactivity in IgE epitopes and T cell epitopes has been reported between major birch p...
Birch pollen-allergic subjects produce polyclonal cross-reactive IgE antibodies that mediate pollen-...
We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both f...
Specific allergen immunotherapy (SIT) is disease-modifying and efficacious. However, the use of who...
IgE-mediated allergy to birch pollen affects more than 100 million patients world-wide. Bet v 1, a 1...
Background Allergy vaccines should be easily applicable, safe, and efficacious. For Bet v 1mediated...
A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes u...
Careful selection of dominant T cell epitope peptides of major allergens that display degeneracy for...
Background. Specific immunotherapy using recombinant allergens is clinically effective; still wild-t...
Background. Specific immunotherapy using recombinant allergens is clinically effective; still wild-t...
BackgroundBet v 1 is the main sensitizing allergen in birch pollen. Like many other major allergens,...
BACKGROUND: Synthetic contiguous overlapping peptides (COPs) may represent an alternative to allerge...
Allergen-reactive CD4+ T cells are implicated in the pathogenesis of allergic disease. Peptide immun...
<p>IgE binding properties of Bet v 1.0401 batches were tested by ELISA. Results are presented as mea...
Background Recombinant hypoallergenic allergen derivatives have been used in clinical immunotherapy ...
ABSTRACTCross-reactivity in IgE epitopes and T cell epitopes has been reported between major birch p...
Birch pollen-allergic subjects produce polyclonal cross-reactive IgE antibodies that mediate pollen-...
We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both f...
Specific allergen immunotherapy (SIT) is disease-modifying and efficacious. However, the use of who...